54,629 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Purchased by Edgestream Partners L.P.

Edgestream Partners L.P. bought a new position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 54,629 shares of the biopharmaceutical company's stock, valued at approximately $3,997,000. Edgestream Partners L.P. owned 0.05% of Intra-Cellular Therapies at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in ITCI. Summit Securities Group LLC bought a new position in Intra-Cellular Therapies in the second quarter worth approximately $56,000. Capital Performance Advisors LLP bought a new position in shares of Intra-Cellular Therapies in the 3rd quarter worth $74,000. CWM LLC lifted its stake in shares of Intra-Cellular Therapies by 83.9% during the 2nd quarter. CWM LLC now owns 1,372 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 626 shares during the last quarter. Covestor Ltd boosted its position in Intra-Cellular Therapies by 40.4% during the third quarter. Covestor Ltd now owns 1,811 shares of the biopharmaceutical company's stock valued at $133,000 after purchasing an additional 521 shares in the last quarter. Finally, Assetmark Inc. grew its stake in Intra-Cellular Therapies by 9.1% in the third quarter. Assetmark Inc. now owns 2,477 shares of the biopharmaceutical company's stock valued at $181,000 after purchasing an additional 207 shares during the last quarter. Institutional investors own 92.33% of the company's stock.

Insider Buying and Selling

In other Intra-Cellular Therapies news, President Michael Halstead sold 22,869 shares of the company's stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total value of $2,038,085.28. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 2.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Cantor Fitzgerald restated an "overweight" rating and issued a $130.00 price target on shares of Intra-Cellular Therapies in a report on Monday, September 16th. The Goldman Sachs Group cut their price target on shares of Intra-Cellular Therapies from $77.00 to $74.00 and set a "neutral" rating on the stock in a report on Thursday, August 8th. Needham & Company LLC reaffirmed a "buy" rating and set a $100.00 price target on shares of Intra-Cellular Therapies in a research report on Wednesday, October 30th. UBS Group lowered their price objective on Intra-Cellular Therapies from $83.00 to $79.00 and set a "neutral" rating for the company in a research report on Thursday, August 8th. Finally, Royal Bank of Canada upped their target price on Intra-Cellular Therapies from $106.00 to $108.00 and gave the company an "outperform" rating in a research report on Friday, October 4th. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $97.23.

Intra-Cellular Therapies Trading Down 1.1 %

NASDAQ ITCI traded down $0.94 on Friday, hitting $85.65. 275,834 shares of the company's stock traded hands, compared to its average volume of 582,609. The firm's 50-day moving average price is $80.27 and its two-hundred day moving average price is $75.55. The firm has a market capitalization of $9.08 billion, a PE ratio of -98.45 and a beta of 0.97. Intra-Cellular Therapies, Inc. has a 1-year low of $58.92 and a 1-year high of $93.45.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The business had revenue of $175.40 million during the quarter, compared to analysts' expectations of $172.30 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. Intra-Cellular Therapies's revenue for the quarter was up 39.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.25) earnings per share. On average, research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.